198 related articles for article (PubMed ID: 19332188)
1. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review.
Oudiz RJ; Farber HW
Am Heart J; 2009 Apr; 157(4):625-35. PubMed ID: 19332188
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.
de Jesus Perez VA; Rosenzweig E; Rubin LJ; Poch D; Bajwa A; Park M; Jain M; Bourge RC; Kudelko K; Spiekerkoetter E; Liu J; Hsi A; Zamanian RT
Am J Cardiol; 2012 Nov; 110(10):1546-50. PubMed ID: 22853986
[TBL] [Abstract][Full Text] [Related]
3. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
5. Prostanoid therapy for pulmonary arterial hypertension.
Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
Mathier MA; McDevitt S; Saggar R
J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
[TBL] [Abstract][Full Text] [Related]
7. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
8. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
Gessler T; Seeger W; Schmehl T
Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
[TBL] [Abstract][Full Text] [Related]
9. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension.
Gomberg-Maitland M; McLaughlin V; Gulati M; Rich S
Am J Cardiol; 2005 Nov; 96(9):1334-6. PubMed ID: 16253609
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension.
Sadushi-Koliçi R; Skoro-Sajer N; Zimmer D; Bonderman D; Schemper M; Klepetko W; Glatz J; Jakowitsch J; Lang IM
J Heart Lung Transplant; 2012 Jul; 31(7):735-43. PubMed ID: 22480725
[TBL] [Abstract][Full Text] [Related]
12. The search for an oral prostanoid to treat pulmonary arterial hypertension continues. Are we getting any closer?
Rich J; Hoeper MM
Int J Clin Pract Suppl; 2009 Mar; (161):17-8. PubMed ID: 19178601
[TBL] [Abstract][Full Text] [Related]
13. Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension.
Reisbig KA; Coffman PA; Floreani AA; Bultsma CJ; Olsen KM
Ann Pharmacother; 2005 Apr; 39(4):739-43. PubMed ID: 15755791
[TBL] [Abstract][Full Text] [Related]
14. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies.
Voswinckel R; Enke B; Reichenberger F; Kohstall M; Kreckel A; Krick S; Gall H; Gessler T; Schmehl T; Ghofrani HA; Schermuly RT; Grimminger F; Rubin LJ; Seeger W; Olschewski H
J Am Coll Cardiol; 2006 Oct; 48(8):1672-81. PubMed ID: 17045906
[TBL] [Abstract][Full Text] [Related]
15. Treprostinil for pulmonary hypertension.
Vachiéry JL; Naeije R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
[TBL] [Abstract][Full Text] [Related]
16. Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension.
Narine L; Hague LK; Walker JH; Vicente C; Schilz R; Desjardins O; Einarson TR; Iskedjian M
Curr Med Res Opin; 2005 Dec; 21(12):2007-16. PubMed ID: 16368052
[TBL] [Abstract][Full Text] [Related]
17. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H
Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
[TBL] [Abstract][Full Text] [Related]
18. Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.
Siehr SL; Ivy DD; Miller-Reed K; Ogawa M; Rosenthal DN; Feinstein JA
J Heart Lung Transplant; 2013 May; 32(5):546-52. PubMed ID: 23453572
[TBL] [Abstract][Full Text] [Related]
19. Advances in prostanoid infusion therapy for pulmonary arterial hypertension.
Doran A; Harris S; Goetz B
J Infus Nurs; 2008; 31(6):336-45. PubMed ID: 19018187
[TBL] [Abstract][Full Text] [Related]
20. Treprostinil: new drug. Pulmonary artery hypertension: just another (disappointing) prostacycline analogue.
Prescrire Int; 2006 Oct; 15(85):177-9. PubMed ID: 17128524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
